SERPINA4 and type 2 diabetes mellitus: Considering the well-established role of low LDL size in cardiovascular risk prediction [14], the negative correlations between mean LDL size and kallistatin levels in T2D and NDO patients may support the antiatherogenic nature of kallistatin.